Key facts
- Notable investors include Oost NL, Torrey Pines Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Mair Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mair Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mair Therapeutics
Operator of TMEM175 agonist therapeutics intended to treat Parkinson's disease and related neurological disorders. The company offers drug candidates targeting TMEM175 pathways and lysosomal function mechanisms, enabling pharmaceutical researchers and healthcare institutions to study and develop treatments for neurodegenerative conditions.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Founded
- 2024
- Employees
- 1
- Website
- mairtx.com/
- Ownership
- Privately Held (backing)
Mair Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mair Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mair Therapeutics in its N-PORT filings yet. We sweep new filings monthly.